Alvotech (ALVO) Competitors

Alvotech logo
$4.46 +0.09 (+1.95%)
As of 01:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ALVO vs. SRRK, GRAL, COGT, ERAS, and PTCT

Should you buy Alvotech stock or one of its competitors? Alvotech's main competitors and comparable companies include Scholar Rock (SRRK), GRAIL (GRAL), Cogent Biosciences (COGT), Erasca (ERAS), and PTC Therapeutics (PTCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alvotech compare to Scholar Rock?

Alvotech (NASDAQ:ALVO) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, Alvotech had 5 more articles in the media than Scholar Rock. MarketBeat recorded 24 mentions for Alvotech and 19 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.40 beat Alvotech's score of 0.19 indicating that Scholar Rock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
5 Very Positive mention(s)
3 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Scholar Rock
4 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alvotech has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.24$27.92M-$0.82N/A
Scholar RockN/AN/A-$377.94M-$3.36N/A

Alvotech has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scholar Rock has a net margin of 0.00% compared to Alvotech's net margin of -50.62%. Alvotech's return on equity of 0.00% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech-50.62% N/A -11.71%
Scholar Rock N/A -175.27%-86.66%

Alvotech currently has a consensus target price of $8.40, suggesting a potential upside of 92.22%. Scholar Rock has a consensus target price of $69.50, suggesting a potential upside of 54.17%. Given Alvotech's higher probable upside, equities analysts clearly believe Alvotech is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43
Scholar Rock
2 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.82

Summary

Alvotech and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks.

How does Alvotech compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Alvotech has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRAIL$147.17M32.35-$408.35M-$9.50N/A
Alvotech$588.90M2.24$27.92M-$0.82N/A

GRAIL has a beta of 2.86, suggesting that its share price is 186% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

GRAIL presently has a consensus price target of $128.80, indicating a potential upside of 21.65%. Alvotech has a consensus price target of $8.40, indicating a potential upside of 92.22%. Given Alvotech's stronger consensus rating and higher probable upside, analysts plainly believe Alvotech is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43

Alvotech has a net margin of -50.62% compared to GRAIL's net margin of -243.80%. Alvotech's return on equity of 0.00% beat GRAIL's return on equity.

Company Net Margins Return on Equity Return on Assets
GRAIL-243.80% -16.13% -14.38%
Alvotech -50.62%N/A -11.71%

In the previous week, Alvotech had 20 more articles in the media than GRAIL. MarketBeat recorded 24 mentions for Alvotech and 4 mentions for GRAIL. GRAIL's average media sentiment score of 0.66 beat Alvotech's score of 0.19 indicating that GRAIL is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRAIL
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alvotech
5 Very Positive mention(s)
3 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Alvotech beats GRAIL on 9 of the 12 factors compared between the two stocks.

How does Alvotech compare to Cogent Biosciences?

Alvotech (NASDAQ:ALVO) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

In the previous week, Alvotech had 18 more articles in the media than Cogent Biosciences. MarketBeat recorded 24 mentions for Alvotech and 6 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.33 beat Alvotech's score of 0.19 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
5 Very Positive mention(s)
3 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Cogent Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Cogent Biosciences has a net margin of 0.00% compared to Alvotech's net margin of -50.62%. Alvotech's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech-50.62% N/A -11.71%
Cogent Biosciences N/A -79.74%-45.67%

Alvotech has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.24$27.92M-$0.82N/A
Cogent BiosciencesN/AN/A-$328.94M-$2.25N/A

Alvotech has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Alvotech presently has a consensus target price of $8.40, suggesting a potential upside of 92.22%. Cogent Biosciences has a consensus target price of $53.57, suggesting a potential upside of 92.36%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43
Cogent Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Summary

Alvotech and Cogent Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Alvotech compare to Erasca?

Alvotech (NASDAQ:ALVO) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Alvotech presently has a consensus target price of $8.40, suggesting a potential upside of 92.22%. Erasca has a consensus target price of $23.17, suggesting a potential upside of 66.79%. Given Alvotech's higher possible upside, research analysts clearly believe Alvotech is more favorable than Erasca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43
Erasca
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alvotech has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Erasca has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Alvotech has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.24$27.92M-$0.82N/A
ErascaN/AN/A-$124.55M-$0.99N/A

Erasca has a net margin of 0.00% compared to Alvotech's net margin of -50.62%. Alvotech's return on equity of 0.00% beat Erasca's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech-50.62% N/A -11.71%
Erasca N/A -31.63%-27.57%

In the previous week, Erasca had 3 more articles in the media than Alvotech. MarketBeat recorded 27 mentions for Erasca and 24 mentions for Alvotech. Alvotech's average media sentiment score of 0.19 beat Erasca's score of 0.18 indicating that Alvotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
5 Very Positive mention(s)
3 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Erasca
3 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Alvotech beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Alvotech compare to PTC Therapeutics?

Alvotech (NASDAQ:ALVO) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Alvotech currently has a consensus price target of $8.40, indicating a potential upside of 92.22%. PTC Therapeutics has a consensus price target of $99.23, indicating a potential upside of 64.40%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43
PTC Therapeutics
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.73

PTC Therapeutics has higher revenue and earnings than Alvotech. PTC Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.24$27.92M-$0.82N/A
PTC Therapeutics$1.73B2.91$682.64M-$1.40N/A

PTC Therapeutics has a net margin of -9.17% compared to Alvotech's net margin of -50.62%.

Company Net Margins Return on Equity Return on Assets
Alvotech-50.62% N/A -11.71%
PTC Therapeutics -9.17%N/A -0.10%

Alvotech has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

In the previous week, Alvotech had 20 more articles in the media than PTC Therapeutics. MarketBeat recorded 24 mentions for Alvotech and 4 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.91 beat Alvotech's score of 0.19 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
5 Very Positive mention(s)
3 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
PTC Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

PTC Therapeutics beats Alvotech on 10 of the 14 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVO vs. The Competition

MetricAlvotechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.34B$4.00B$7.66B$11.73B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio-5.4024.7134.0030.04
Price / Sales2.2815.848.445.70
Price / Cash20.2122.9521.0121.90
Price / Book-5.014.194.483.75
Net Income$27.92M-$24.10M$3.51B$394.12M
7 Day Performance-9.45%-7.66%-5.93%-5.63%
1 Month Performance-10.90%-5.73%-4.31%-6.93%
1 Year Performance-12.82%-6.16%-1.15%-7.12%

Alvotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVO
Alvotech
3.789 of 5 stars
$4.46
+1.9%
$8.40
+88.6%
-15.0%$1.34B$588.90MN/A1,460
SRRK
Scholar Rock
3.2862 of 5 stars
$48.00
-6.9%
$67.67
+41.0%
+23.6%$5.85BN/AN/A289
GRAL
GRAIL
2.472 of 5 stars
$124.74
-2.6%
$128.80
+3.3%
+24.7%$5.57B$147.17MN/A910
COGT
Cogent Biosciences
2.8313 of 5 stars
$31.64
-5.7%
$53.57
+69.3%
-17.5%$5.49BN/AN/A258
ERAS
Erasca
1.8319 of 5 stars
$15.48
-0.8%
$22.09
+42.7%
+384.0%$5.41BN/AN/A103

Related Companies and Tools


This page (NASDAQ:ALVO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners